Autolus Therapeutics Ltd - Asset Resilience Ratio

Latest as of March 2026: 18.69%

Autolus Therapeutics Ltd (AUTL) has an Asset Resilience Ratio of 18.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$98.51 Million

Cash + Short-term Investments

Total Assets

$527.07 Million

All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2023–2025)

This chart shows how Autolus Therapeutics Ltd's Asset Resilience Ratio has changed over time. Check Autolus Therapeutics Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Autolus Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Autolus Therapeutics Ltd market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$98.51 Million	18.69%
Total Liquid Assets	$98.51 Million	18.69%

Asset Resilience Insights

Good Liquidity Position: Autolus Therapeutics Ltd maintains a healthy 18.69% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Autolus Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Autolus Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for Autolus Therapeutics Ltd (2023–2025)

The table below shows the annual Asset Resilience Ratio data for Autolus Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	33.37%	$196.58 Million	$589.07 Million	-12.70pp
2024-12-31	46.08%	$360.64 Million	$782.73 Million	--
2023-12-31	0.00%	$0.00	$375.38 Million	--

pp = percentage points

About Autolus Therapeutics Ltd

NASDAQ:AUTL USA Biotechnology

Market Cap

$396.55 Million

Market Cap Rank

#13281 Global

#3222 in USA

Share Price

$1.49

Change (1 day)

-2.61%

52-Week Range

$1.21 - $2.47

All Time High

$48.01